PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis

Inclusion Criteria:

1. Written informed consent (and assent when applicable) obtained from participant or
participant's legal representative

2. Enrolled in the CFF Patient Registry (CFF PR)

3. Be willing and able to adhere to study procedures in the context of clinical care, and
other protocol requirements

4. Male or female participant ≥ 6 years of age at enrollment who are able to reliably
expectorate sputum and/or willing to undergo sputum induction (if necessary)

5. Diagnosis of CF consistent with the 2017 CFF Guidelines

6. NTM positive for a species or sub-species in the 2 years prior to enrollment that has
never been treated.

7. Willing to discontinue chronic azithromycin use for the duration of the study

Exclusion Criteria:

1. Prior or ongoing antibiotic treatment of the same NTM species or sub-species for which
the patient is being considered for this study

2. History of solid organ or hematological transplantation

3. Has any other condition that, in the opinion of the Site Investigator/designee, would
preclude informed consent or assent, make study participation unsafe, complicate
interpretation of study outcome data, or otherwise interfere with achieving the study
objectives